New solutions support high-precision analytics for process development, batch release and regulatory compliance and enable a standardized workflow
1 in 3 Phase II trials were terminated in 2024
The UG 100 offers a cost-effective and extremely low-error sequencing profile
Dive into a new era of intelligence and performance with Agilent's upcoming virtual launch
By developing rapid, accurate, and cost-effective lateral flow tests for prostate cancer, Valley Diagnostics aims to make early diagnosis more accessible and reliable
Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques
Drug Discovery returns to Liverpool, 21–22 October 2025 to celebrate 'A Festival of Life Science'
The Adeno-Associated Virus will be used in a Phase 1 trial in patients with advanced, high-risk acute myeloid leukemia.
Hear expert insights on ADC innovations, manufacturing challenges, and the future of precision medicine
New test format enhances commercialisation potential
Successful project delivery of Optimer binders with proven function as vaccine adjuvants
Since 2021, only 14% of rivers in England achieved ‘good’ ecological status and none received an overall ‘good’ classification from the Environment Agency
Dr. Murakami discusses the molecular tools enabling the pursuit of precision medicine
Technology advances, coupled with collaborations between equipment makers and healthcare organizations, are improving early detection of blood cancers in Africa
Accuracy in ESR1 mutation testing means the difference between treatment and resistance — now a new ESR1 control kit ensures reliable results
From spreadsheet silos to AI-powered insights, discover how Signals software is streamlining formulation science
Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling
The VENTANA TROP2 (EPR20043) RxDx Device is an immunohistochemistry (IHC) assay combined with a digital pathology algorithm to determine patient treatment
Grifols and IBL, a Tecan company, seek to revolutionize clinical diagnostics with a future high-sensitivity, multiplexed immunoassay platform
Breakthrough status provides expedited review and closer collaboration with the FDA, ultimately enabling broader market reach and commercial adoption
Redipor by AnalytiChem combining 150+ years of expertise in high-quality prepared media, now manufactured in three production facilities worldwide
With intuitive workflows, quick setup, and expert support, Veya is making automation accessible and cost-effective for first-time users
